Comment on: Immunotherapy-based firstline treatment of intermediate- and poorrisk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system
J. bras. econ. saúde (Impr.); 14 (3), 2022